The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R03 | Drugs for obstructive airway diseases | |
| 3 | R03A | Adrenergics, inhalants | |
| 4 | R03AL | Adrenergics in combination with anticholinergics | |
| 5 | R03AL03 | Vilanterol and umeclidinium bromide |
| Active Ingredient | Description | |
|---|---|---|
| Vilanterol |
Vilanterol is a selective long-acting, beta2-adrenergic agonist (LABA). The pharmacologic effects of beta2-adrenoceptor agonist active substances, including vilanterol, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. |
|
| Vilanterol and Umeclidinium bromide |
Umeclidinium/vilanterol is a combination inhaled long-acting muscarinic receptor antagonist/long-acting beta2-adrenergic agonist (LAMA/LABA). Following oral inhalation both compounds act locally on airways to produce bronchodilation by separate mechanisms. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ANORO ELLIPTA Inhalation powder, pre-dispensed | European Medicines Agency (EU) | MPI, EU: SmPC | |
| LAVENTAIR Inhalation powder, pre-dispensed | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
